Fig. 1From: Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trialAlgorithm for the management of A diarrhea adverse events and B hepatic enzyme elevations in the INBUILD trialBack to article page